Developing Therapeutics That Teach the Body to Heal Itself
BLOG ARCHIVES
Category: HIV
HIV Has Been Cured For a 5th Time, Now Researchers Are Developing Scalable Methods
Contributing Author Luke Williams, Sales and Marketing A mounting body of evidence shows that HIV, once thought to be an incurable lifelong condition, is indeed curable. The “Dusseldorf Patient” made headlines recently when a stem cell transplant to treat life-threatening cancer also cured him of HIV. However, the transplantation method is incredibly dangerous and the availability of rare, HIV-resistant donor… [Read More]
American Gene Technologies Celebrates Another Year of Progress
Contributing Author John Vandermosten, Senior Biotechnology Analyst In 2022, the world was collectively compelled to endure a surge in viral outbreaks, the horror of the Russia-Ukraine war and rampant inflation, which has led many to a state of pessimism. But, the dramatic events of 2022 have overshadowed other, more reassuring news. In contrast to the gloom of this daily news cycle,… [Read More]
Phase 1 HIV Clinical Trial Data Published in “Frontiers in Medicine” Journal
Contributing Author Luke Williams, Sales and Marketing American Gene Technologies® (AGT) designed AGT103-T in hopes of functionally curing HIV. The therapeutic is made of the patient’s own T cells which have been enhanced for HIV resistance, and data from the Phase 1 human trial has recently been published in the journal Frontiers in Medicine. HIV is a curable condition, as… [Read More]
2021 IPO & M&A Trends
Contributing Author John Vandermosten, Senior Biotechnology Analyst Transaction Trends 2021: Pandora’s Box 2020 was a tremendous year for Initial Public Offerings (IPOs) where 494 new issues came to market[1], but the achievement was eclipsed in 2021 with an all-time record of 1,058 companies going public. In healthcare/life sciences, we counted 118 IPOs in 2020, rising to an impressive 147 in 2021. … [Read More]
Chapter IV: Solving The Riddle, A Consequential Approach
Contributing Author John Vandermosten, Senior Biotechnology Analyst The arc of HIV history has been developing over the last four decades. In the early days there was much we did not know, but as teams of physicians, researchers and patients increased their understanding of the disease, progress was made. Early efforts with repurposed cancer drugs gave way to numerous viral inhibitor combinations. … [Read More]
The Berlin Patient’s Success Produces A Flurry of Activity
The Berlin Patient’s success provided optimism that there was a way to permanently disable HIV and eradicate it from an infected person. While a bone marrow transplant is not appropriate for most HIV patients, what we have learned from his experience has provided us clues to find a cure. Removing the door handle HIV uses to gain entry to immune… [Read More]
Why Is It So Difficult to Find an HIV Cure?
More than 32 million people have died from AIDS-related illnesses since the start of the epidemic in 1981, making HIV/AIDS one of the greatest public health threats the world has known. Since it was first identified nearly 40 years ago, trillions of dollars have been spent by governments and private individuals on efforts to find effective treatments, vaccines, and a… [Read More]
ARC of HIV History 2 – A Beginning and an End
Contributing Author John Vandermosten, Senior Biotechnology Analyst This is the second installment of our series on the Arc of HIV History which examines the earliest emergence of HIV and the progress that has been made until today. In Part 2 we look at the genesis of the first approved HIV drug and the first cure of HIV in the Berlin Patient…. [Read More]
In Memory of Timothy Ray Brown
Contributing Author : Jeff Galvin, CEO and Founder American Gene Technologies A Message From the CEO of American Gene Technologies® Timothy Ray Brown – March 11, 1966 – September 29, 2020 Timothy Ray Brown was both a person and a turning point in the arc of HIV history. Timothy received a bone marrow transplant and became functionally cured; a symbol… [Read More]
AGT™ Announces First-Ever Reddit AMA on the Potential of Gene Therapies
We are proud to have participated in our first-ever Reddit AMA on April 21, 2016. AGT CEO, Jeff Galvin and Chief Science Officer, Dr. David Pauza discussed the future of gene therapy and viral vectors as a delivery vehicle. See the full Reddit AMA HERE ****************test*************** Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum… [Read More]
Subscribe to Our Newsletter
Subscribe to our newsletter to keep up to date with all the latest news about AGT!
